Skip to Content
CellsCells
  • Review
  • Open Access

20 May 2021

16 Pages

The Complexity of FGF23 Effects on Cardiomyocytes in Normal and Uremic Milieu

,
and
1
Department of Internal Medicine, Medical Faculty, University of Banja Luka, 78000 Banja Luka, Republic of Srpska, Bosnia and Herzegovina
2
Institute of Anatomy, University of Zurich, 8057 Zurich, Switzerland
3
Department of Nephrology, Faculty of Medicine, University of Medicine Tirana, 1001 Tirana, Albania
4
Department of Nephrology, Medical Faculty, University of Ss. Cyril and Methodius, 1000 Skopje, North Macedonia

Abstract

Fibroblast growth factor-23 (FGF23) appears to be one of the most promising biomarkers and predictors of cardiovascular risk in patients with heart disease and normal kidney function, but moreover in those with chronic kidney disease (CKD). This review summarizes the current knowledge of FGF23 mechanisms of action in the myocardium in the physiological and pathophysiological state of CKD, as well as its cross-talk to other important signaling pathways in cardiomyocytes. In this regard, current therapeutic possibilities and future perspectives are also discussed.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.